RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Focal Onset Seizures

In brief

This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures.

Key facts

Study ID: NCT06798896
Run by: Supernus Pharmaceuticals, Inc.
People needed: 216
Starts: 2024-12-30
Expected to finish: 2027-08-01
Last updated by the study team: 2026-06-01

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Diagnosis of treatment-resistant focal epilepsy as adjudicated by the Epilepsy Study Consortium, Inc (ESCI);
Failed to achieve sustained seizure freedom after ≥2 tolerated, appropriately chosen, and adequately dosed ASM drug schedules;
Able to keep accurate Seizure electronic diaries [eDiaries] (with the aid of a caregiver as needed);
Has a body mass index (BMI) between 18.0 and 40.0 kg/m2;
Treatment with a stable dose of 1 to 4 current ASMs for ≥28 days prior to screening. If following a diet plan along with the ASM, the participant should have been on a stable diet plan for at least 1 month prior to Visit 1. The diet plan should be maintained throughout the duration of the study;
At least 4 clinically observable focal onset seizures accepted by the ESCI prior to the first dose of SM (during the days of baseline Seizure electronic diary [eDiary] data collection) and no more than a consecutive 21-day period that was free of these seizures. To be eligible for the study, participants must comply with the eDiary on at least 80% of the days of baseline data collection;

You may not qualify if…

Has taken huperzine A within the past 6 months;
Prior diagnosis of combined focal and generalized epilepsy syndrome as evidenced by severe developmental delay and multiple seizure types and confirmed by electroencephalography (EEG) (eg, Lennox-Gastaut syndrome). Participants should also be excluded in case of nondiagnostic information;
History of or current nonepileptic events that could be confused by the participant and/or study staff as epileptic seizures;
Only has seizures that are difficult to count; for example, seizures that are not clinically observable;
History of uncountable seizures, such as seizures that happen in a cluster that are too rapid to be counted individually;
History of status epilepticus within 6 months prior to screening;
Vagus nerve stimulation, deep brain stimulation, responsive neurostimulator system, or other neurostimulation for epilepsy device implanted or activated within 1 year prior to screening; or epilepsy surgery within 1 year prior to screening. Stimulation parameters for devices must have been stable for at least 3 months prior to Screening. Battery change for any epilepsy devices will be allowed; however, stimulation parameters must remain stable during the duration of the study;
Any suicidal behavior or suicidal ideation related to item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) based on the C-SSRS assessment in the 1 year before screening; a suicide attempt in the last 2 years before screening; or more than 1 lifetime suicide attempt;
Chronic concomitant therapy with non-ASMs that have potent cholinergic (central or peripheral) or potent central (only) anticholinergic pharmacology.
History of >2 allergic reactions to an ASM or 1 serious hypersensitivity reaction to an ASM;
Any other reason which, in the opinion of the Investigator, would prevent the participant from taking part in the study.

Where it is running

Medsol Clinical Research Center — Port Charlotte, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.